\n\u00a0<\/p>\n
\n\tOncology currently makes a negligible contribution to GSK India\u2019s revenue. How materially can it contribute over the next five years?<\/p>\n
\u00a0<\/p>\n
\n\tMore than a decade ago, we had an oncology business that was divested in a global asset-swap deal with Novartis.\u00a0 We are rebuilding those muscles, but what is heartening is the pipeline. We launched our oncology business in gynaecological malignancies with Jemperli for primary advanced and recurrent endometrial cancer and Zejula for recurrent ovarian cancer.<\/p>\n
\u00a0<\/p>\n
\n\tWe have received approval for Blenrep for second-line treatment of relapsed or refractory multiple myeloma, and it will be launched shortly. We also plan to launch Omjjara for myelofibrosis within the next 12 months.<\/p>\n
\u00a0<\/p>\n
\n\tEvery indication is like a product launch and adds heft to the flywheel. Over the next five years, I see oncology as the biggest arrowhead of our growth strategy. I certainly see the oncology business reaching around \u20b9750 crore to \u20b91,000 crore over five years. These are directional numbers.<\/p>\n
\u00a0<\/p>\n
\n\tHow is India\u2019s participation in GSK\u2019s clinical trials helping accelerate product launches?<\/p>\n
\u00a0<\/p>\n
\n\tWhen I got this job four years ago, the number was around 12 or 13 trials. As we speak, 33 global and local clinical trials are ongoing or planned, of which 27 are pivotal studies that form part of the global clinical-trial road map.<\/p>\n
\u00a0<\/p>\n
\n\tOver the past 24 months, we have ensured that India is on the clinical-development footprint for every global asset. Indian patients participate in these trials, and the resulting safety and efficacy data can be presented to the Central Drugs Standard Control Organisation (CDSCO) to support accelerated launches. Blenrep is an example. We received India\u2019s approval this June, and it will be launched shortly. Bepirovirsen, our chronic-hepatitis-B asset, is expected to be launched within the next 12 months. India participated in the global phase-III B-Well 1 and B-Well 2 trials, enrolling more than 100 patients.<\/p>\n
\u00a0<\/p>\n
\n\tHow do you see the balance between GSK\u2019s paediatric and adult vaccine businesses changing?<\/p>\n
\u00a0<\/p>\n
\n\tPaediatric vaccines will remain important because 26 million babies are born in India every year. Every seven seconds, a baby in India is vaccinated with a GSK vaccine. The vaccine business contributes more than \u20b9750 crore out of our nearly \u20b94,000-crore business.<\/p>\n
\u00a0<\/p>\n
\n\tBefore Covid-19, the adult-vaccination ecosystem was almost non-existent. From that standing start, the shingles-prevention vaccine Shingrix is now a \u20b9100-crore brand on a moving-annual-total basis. Nearly 20,000 patients take the vaccine every month, and Shingrix is growing exponentially.<\/p>\n
\u00a0<\/p>\n
\n\tWe have also received marketing authorisation from the Drugs Controller General of India (DCGI) for Arexvy, a vaccine that prevents lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in older adults and high-risk groups.<\/p>\n
\u00a0<\/p>\n
\n\tWe plan to launch it within the next 12 months. Paediatric vaccines will remain important because of the birth cohort, but adult vaccines will be significantly transformational over the next three to five years.<\/p>\n
\u00a0<\/p>\n
\n\tWhat are your revenue and margin ambitions as the portfolio changes?<\/p>\n
\u00a0<\/p>\n
\n\tOur ambition is to grow the business to \u20b98,000 crore by FY30. That ambition remains undiluted.<\/p>\n
\u00a0<\/p>\n
\n\tWe have a laser-sharp focus on operational efficiency, expanding gross margin and removing inefficiencies and costs from the factory and supply chain. Our objective is to sustain margins at current levels while growing the top line.<\/p>\n
\u00a0<\/p>\n
\n\tOne advantage is that the global organisation finances the R&D effort, including clinical trials. Oncology and haematology assets do not require field forces of 2,000 or 3,000 people; they may require only 20 or 30 highly capable, science-led team members. Each of these assets could be worth \u20b9300 crore to \u20b9500 crore individually.<\/p>\n
\u00a0<\/p>\n
\n\tWith greater focus on specialty products, what role will the general medicines business play?<\/p>\n
\u00a0<\/p>\n
\n\tMore than 70 per cent of our total business comes from general medicines, and almost 95-97 per cent of it is locally manufactured, both at our Nashik factory and through partners.<\/p>\n
\u00a0<\/p>\n
\n\tWe have made strategic choices around areas where we still have the science. We continue to invest in anti-infectives, dermatology and pain. Calpol remains the country\u2019s number-one paracetamol brand, while Augmentin continues to be one of our leading brands.<\/p>\n
\u00a0<\/p>\n
\n\tThese are not merely trademarks for us; they are trust marks. General medicines will continue to be an important platform. I do not see these brands becoming less relevant.<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 Oncology currently makes a negligible contribution to GSK India\u2019s revenue. How materially can it contribute over…\n","protected":false},"author":2,"featured_media":104643,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[43820,43819,43824,43817,43812,21120,22180,43823,20785,43822,43809,43813,43810,43808,43811,43814,43825,36211,43816,43821,43818,43815],"class_list":["post-104642","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-adult-vaccines-india","tag-arexvy-india","tag-augmentin","tag-bepirovirsen","tag-bhushan-akshikar","tag-blenrep","tag-calpol","tag-general-medicines-gsk","tag-gsk","tag-gsk-clinical-trials-india","tag-gsk-india-fy30","tag-gsk-india-md","tag-gsk-india-oncology-business","tag-gsk-india-revenue-target","tag-gsk-india-vaccines","tag-gsk-oncology-india","tag-indian-pharmaceutical-industry","tag-jemperli","tag-omjjara","tag-paediatric-vaccines-india","tag-shingrix-india","tag-zejula"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117106594502542623","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/104642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=104642"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/104642\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/104643"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=104642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=104642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=104642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}